Fintel reports that on September 14, 2023, Cantor Fitzgerald reiterated coverage of EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Overweight recommendation.
Analyst Price Forecast Suggests 194.41% Upside
As of August 31, 2023, the average one-year price target for EyePoint Pharmaceuticals is 32.38. The forecasts range from a low of 22.22 to a high of $57.75. The average price target represents an increase of 194.41% from its latest reported closing price of 11.00.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for EyePoint Pharmaceuticals is 34MM, a decrease of 8.60%. The projected annual non-GAAP EPS is -2.69.
What is the Fund Sentiment?
There are 187 funds or institutions reporting positions in EyePoint Pharmaceuticals. This is an increase of 9 owner(s) or 5.06% in the last quarter. Average portfolio weight of all funds dedicated to EYPT is 0.20%, an increase of 228.00%. Total shares owned by institutions increased in the last three months by 7.09% to 35,056K shares. 
The put/call ratio of EYPT is 2.36, indicating a bearish outlook.
What are Other Shareholders Doing?
Franklin Resources holds 5,065K shares representing 14.48% ownership of the company. In it's prior filing, the firm reported owning 5,778K shares, representing a decrease of 14.09%. The firm increased its portfolio allocation in EYPT by 145.72% over the last quarter.
Essex Woodlands Management holds 4,191K shares representing 11.98% ownership of the company. No change in the last quarter.
Suvretta Capital Management holds 3,424K shares representing 9.79% ownership of the company. In it's prior filing, the firm reported owning 3,395K shares, representing an increase of 0.85%. The firm increased its portfolio allocation in EYPT by 277.74% over the last quarter.
Ra Capital Management holds 3,371K shares representing 9.63% ownership of the company. No change in the last quarter.
Cormorant Asset Management holds 3,200K shares representing 9.15% ownership of the company. In it's prior filing, the firm reported owning 225K shares, representing an increase of 92.97%. The firm increased its portfolio allocation in EYPT by 3,477.14% over the last quarter.
EyePoint Pharmaceuticals Background Information
(This description is provided by the company.)
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
